HENDERSON -
VPG is the first-to-market diagnostic laboratory in the
Volition's Nu.Q Vet Cancer Test is an accessible and affordable screening tool for dogs with increased risk of developing cancer, such as older dogs, certain breeds with higher cancer prevalence rates and those dogs with familial history.
Dr
'By integrating the revolutionary Nu.Q Vet Cancer Test into our diagnostic portfolio, we are expanding our wellness testing offering and empowering veterinarians with an accessible, cutting edge tool to detect cancer in its early stages, ultimately leading to better outcomes and improved patient care.
'Veterinary practices interested in offering the Nu.Q Vet Cancer Test to their clients can find out more at thevpg.co.uk or visit us at stand K11 at the London Vet Show later this month.'
Note: 1. There are approximately 11 million dogs as pets in the
About VPG
VPG are veterinary laboratory diagnostic experts, using scientific excellence, innovation and personalised support to help veterinary practices by delivering Excellence Everywhere. With over 20 years of experience and data, their vision is to set the standard for the Veterinary industry, improving outcomes for animals, pet owners, and their veterinary partners.
By supporting and investing in a team of exceptional people, they aim to provide the best possible advice and care for their clients, with the healthcare of animals at the forefront of everything they do. VPG offer a comprehensive and extensive range of tests as well as diagnostic advice for domestic pets, horses and exotic species.
About Volition
Volition is a multi-national epigenetics company powered by Nu.Q, its proprietary nucleosome quantification platform. Through its subsidiaries, Volition is developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases in humans and animals including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid an indication that disease is present.
Volition's research and development activities are centered in
The contents found at the Volition, VPG and PDSA website addresses are not incorporated by reference into this document and should not be considered part of this document. The website addresses are included in this document as inactive textual references only.
Contact:
Email: mediarelations@volition.com
Tel: +44 (0)7557 774620
Email: catrin.thomas@thevpg.co.uk
Tel: +44 (0)7435 983344
Safe Harbor Statement
Statements in this press release may be 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'aims,' 'targets,' 'believes,' 'seeks,' 'estimates,' 'optimizing,' 'potential,' 'goal,' 'suggests,' 'could,' 'would,' 'should,' 'may,' 'will' and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to the timing and launch of product sales, and the potential uses, benefits and effectiveness of its Nucleosomics technology platform, including the Nu.Q Vet Cancer Test. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests, a failure by the marketplace to accept Volition's, Nu.Q Vet Cancer Test or other products based on its Nucleosomics platform; Volition's failure to secure adequate intellectual property protection; Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; Volition will face fierce competition and its intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring markets and their rapid technological change; downturns in domestic and foreign economies and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the
Nucleosomics and Nu.Q and their respective logos are trademarks and/or service marks of
(C) 2023 Electronic News Publishing, source